RESUMEN
On 11 March 2020, the World Health Organization declared coronavirus disease 19 (COVID-19) a global pandemic. This exceptional situation changed the world not only in terms of mortality and morbidity, but also in terms of epidemiology and health system resources consumption. The objective of this work was to analyze the consumption of antibiotics during the period around the pandemic in our region. A drug utilization study was performed comparing the antibiotic consumption in the community during the years 2018, 2019, 2020, and 2021. Quarterly antibiotic use (defined daily doses (DDD) per 1000 inhabitants per day (DID)) and number of patients treated were the outcomes. Interrupted time series regression analysis was performed to estimate the statistical significance of the change in level of consumption before and after the COVID-19 pandemic. The drop of global antibiotic consumption was statistically significant, both in number of patients and in DID when analyzing pre-pandemic period versus pandemic period. The use of strategic antibiotics for respiratory infections such as amoxicillin, amoxicillin-clavulanic acid, and levofloxacin also decreased significantly. Seasonal pattern of use of antibiotics disappeared due to the global measures imposed over the world to work against COVID-19.
Asunto(s)
Antibacterianos/farmacología , Farmacorresistencia Bacteriana , Macrólidos/farmacología , Infecciones por Mycoplasma/epidemiología , Infecciones por Mycoplasma/microbiología , Mycoplasma genitalium/efectos de los fármacos , Historia del Siglo XXI , Humanos , Infecciones por Mycoplasma/tratamiento farmacológico , Infecciones por Mycoplasma/historia , Mycoplasma genitalium/genética , Países Bajos/epidemiologíaRESUMEN
Objetivo: describir la tuberculosis infantil de 2005 a 2015 en Navarra, con datos demográficos, clínicos, radiológicos, microbiológicos, tratamiento y evolución. Material y métodos: estudio descriptivo retrospectivo a partir de datos de historia clínica de los pacientes atendidos entre 2005 y 2015. Resultados: 52 pacientes, 57,7% varones, 42,3% mujeres, mediana de edad cuatro años, 38,5% inmigrantes, 61,5% hijos de inmigrantes. Distribución homogénea en los diez años, excepto un brote en 2011. Sintomáticos el 69,2%. En el 63,5% de los pacientes el caso índice es conocido. La forma clínica más frecuente es la pulmonar (82,7%). La radiología fue patológica en el 86,5%, se realizó tomografía computarizada pulmonar en el 82,7% (95,3% patológicos). El 71,2% de los cultivos fueron positivos para Mycobacterium tuberculosis (sensibles 92,3%). Tratamiento con cuatro fármacos y posteriormente dos de 6 a 12 meses. Evolución: 84,6% curación, 13,5% secuelas y un exitus. Conclusiones: la tuberculosis es un problema de salud infantil cuya forma más frecuente es pulmonar. Evoluciona favorablemente, pero presenta morbimortalidad. Es imprescindible tenerla en cuenta para diagnóstico y tratamiento precoz
Objective: to describe tuberculosis in Pediatrics from 2005-2015 in Navarra, attending to demographic, clinic, radiologic, microbiologic, treatment and evolution data. Material and methods: a retrospective descriptive study based on data from the clinical history of patients treated between 2005 and 2015. Results: we studied 52 patients, 57.7% men, 42.3% women, age: 4 years old. 38.5% are immigrant and 61.5% children from immigrants. During the last 10 years, the distribution has been homogeneous, despite of one outbreak in 2011. 69.2% had symptoms when diagnosed. In 63.5% we knew index case. The most frequent clinical form is the pulmonary one. Simple Rx was pathological in 86,5% of cases and CT was applied in 82,7% (being diagnostic in 95'3% of them). 71,2% of microbiological cultures were positive for Mycobacterium tuberculosis (92,3% of them were sensible to M. tuberculosis sensible to standard treatment). All patients were treated with four drugs and then two up to 6-12 months. Follow up: 84.6% healed, 13.5% healed but there were sequelae and one of our patients died. Conclusion: tuberculosis represents a problem in children health. Pulmonary tuberculosis is the most frequent clinical form. Normally, it evolves favourably but morbimortality exists. It is essential to consider tuberculosis in order to have an early diagnosis and treatment
Asunto(s)
Humanos , Masculino , Femenino , Lactante , Preescolar , Niño , Adolescente , Tuberculosis/epidemiología , Mycobacterium tuberculosis/aislamiento & purificación , Mycobacterium tuberculosis/patogenicidad , Tuberculosis/prevención & control , Prueba de Tuberculina/métodos , Antituberculosos/uso terapéuticoRESUMEN
OBJECTIVE: The aim was to assess the effect of the nonsystematic pneumococcal conjugate vaccine (PCV) on incidence of pneumonia associated with parapneumonic pleural effusion (PPE) in vaccinated and unvaccinated children. METHODS: Cases were patients <15 years of age who had been diagnosed with pneumonia associated with PPE in a tertiary hospital in Navarra (Spain) between 1995 and 2014. The population <15 years of age and covered by the public health service was used as reference. The vaccination status of the cases and population was obtained from computerized medical records. Logistic regression analyses included vaccination status, age group and time periods: prevaccine (1995-2001) and vaccination with PCV7 (2002-2010) and PCV13 (2011-2014). RESULTS: A total of 321 cases of PPE were included. The risk of PPE increased between the prevaccine and PCV7 period (adjusted odds ratio [OR], 3.34; 95% confidence interval [CI]: 2.37-4.71), while vaccination with PCV7 was found to be an independent risk factor (OR, 1.44; 95% CI: 1.09-1.89) in the same analysis. In the PCV13 period, the risk of PPE returned to the prevaccination incidence level among children vaccinated with PCV13 (OR, 1.07; 95% CI: 0.56-2.04), while unvaccinated children (OR, 1.69; 95% CI: 0.96-2.98) and overall those vaccinated with PCV7 (OR, 3.64; 95% CI: 2.15-6.17) maintained an increased risk of PPE. CONCLUSION: The nonsystematic introduction of PCV7 was followed by an increased incidence of PPE. The subsequent introduction of PCV13 was associated with a return to the incidence level in the prevaccine period, mainly in children vaccinated with PCV13.
Asunto(s)
Vacuna Neumocócica Conjugada Heptavalente/administración & dosificación , Derrame Pleural/epidemiología , Vacunas Neumococicas/administración & dosificación , Neumonía Neumocócica/complicaciones , Neumonía Neumocócica/epidemiología , Adolescente , Niño , Preescolar , Femenino , Hospitales Pediátricos , Humanos , Incidencia , Lactante , Recién Nacido , Masculino , Derrame Pleural/prevención & control , Neumonía Neumocócica/prevención & control , España/epidemiología , Centros de Atención TerciariaRESUMEN
We estimated the direct, indirect and total effects of the 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease (IPD) in children. A population-based cohort study followed children aged between 2.5 and 59 months between 2001 and 2014 in Navarra, Spain. IPD incidence was compared by PCV status and period. All cases diagnosed from July 2010 to December 2014 and eight matched controls per case were analysed to estimate the adjusted direct effect of PCV13. A total of 120,980 children were followed and 206 IPD cases were detected. Compared with unvaccinated children in the baseline period (2001-2004), overall IPD incidence in 2011-2014 (76% average PCV coverage) declined equally in vaccinated (total effect: 76%; hazard ratio (HR): 0.24; 95% confidence interval (CI): 0.14-0.40) and unvaccinated children (indirect effect: 78%; HR: 0.22; 95% CI: 0.09-0.55). IPD incidence from non-PCV13 serotypes increased among vaccinated children (HR: 2.84; 95% CI: 1.02-7.88). The direct effect of one or more doses of PCV13 against vaccine serotypes was 95% (odds ratio: 0.05; 95% CI: 0.01-0.55). PCV13 was highly effective in preventing vaccine-serotype IPD. The results suggest substantial and similar population-level vaccine benefits in vaccinated and unvaccinated children through strong total and indirect effects.
Asunto(s)
Vacunación Masiva/estadística & datos numéricos , Infecciones Neumocócicas/prevención & control , Vacunas Neumococicas/administración & dosificación , Vigilancia de la Población , Serotipificación , Streptococcus pneumoniae/aislamiento & purificación , Estudios de Casos y Controles , Niño , Preescolar , Femenino , Humanos , Incidencia , Lactante , Masculino , Infecciones Neumocócicas/epidemiología , Serogrupo , España/epidemiología , Streptococcus pneumoniae/clasificación , VacunaciónRESUMEN
Pneumococcal conjugate vaccines (PCVs) were licensed for use in children and became available for private purchase in Spain in 2001 (PCV7), 2009 (PCV10) and 2010 (PCV13). This study evaluates changes in the incidence of invasive pneumococcal disease (IPD) and the pattern of serotypes isolated in Navarre, Spain, between the period of use of PCV7 (2004-2009) and that of PCV13 (2010-2013). The percentage of children <2 years who received at least one dose of PCV in these periods ranged from 25 to 61% and 61 to 78%, respectively. Between the periods 2004-2009 and 2010-2013 IPD incidence declined by 37%, from 14.9 to 9.4 cases/100,000 inhabitants (p<0.001). In children <5 years it fell by 69% (p<0.001), in persons aged 5-64 years, by 34% (p<0.001), and in those ≥ 65, by 23% (p=0.024). The incidence of cases due to PCV13 serotypes declined by 81% (p<0.001) in children <5 years and by 52% (p<0.001) in the whole population. No significant changes were seen in the distribution of clinical presentations or in disease severity. The incidence of IPD has declined and the pattern of serotypes causing IPD has changed notably in children and moderately in adults following the replacement of PCV7 by PCV13.
Asunto(s)
Infecciones Neumocócicas/epidemiología , Vacunas Neumococicas/administración & dosificación , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Femenino , Humanos , Incidencia , Lactante , Masculino , Persona de Mediana Edad , Infecciones Neumocócicas/prevención & control , Vigilancia de Guardia , España/epidemiología , Vacunas Conjugadas/administración & dosificación , Adulto JovenAsunto(s)
Absceso Abdominal/etiología , Vacuna BCG/efectos adversos , Vacuna BCG/uso terapéutico , Espacio Retroperitoneal , Neoplasias de la Vejiga Urinaria/complicaciones , Neoplasias de la Vejiga Urinaria/tratamiento farmacológico , Absceso Abdominal/microbiología , Absceso Abdominal/terapia , Anciano , Antituberculosos/uso terapéutico , Humanos , Isoniazida/uso terapéutico , Neoplasias Pulmonares/secundario , Masculino , Mycobacterium tuberculosis , Pirazinamida/uso terapéutico , Tomografía Computarizada por Rayos X , Tuberculosis/complicaciones , Tuberculosis/tratamiento farmacológicoAsunto(s)
Humanos , Masculino , Persona de Mediana Edad , Espacio Retroperitoneal/microbiología , Espacio Retroperitoneal/fisiopatología , Absceso/complicaciones , Absceso/diagnóstico , Enfermedades de la Vejiga Urinaria/complicaciones , Enfermedades de la Vejiga Urinaria/diagnóstico , Neoplasias de la Vejiga Urinaria/complicaciones , Neoplasias de la Vejiga Urinaria/diagnóstico , Espacio Retroperitoneal , Enfermedades de la Vejiga Urinaria/patología , Enfermedades de la Vejiga Urinaria , /métodos , Mycobacterium bovis/aislamiento & purificaciónRESUMEN
Two rotavirus vaccines have been available since 2006. This study evaluates the effectiveness of these vaccines using a test-negative case-control design in Navarre, Spain. We included children 3-59 months of age who sought medical care for gastroenteritis and for whom stool samples were taken between January 2008 and June 2011. About 9% had received the pentavalent vaccine (RotaTeq) and another 8% received the monovalent vaccine (Rotarix). Cases were the 756 children with confirmed rotavirus and controls were the 6036 children who tested negative for rotavirus. Thirty-five percent of cases and 9% of controls had required hospitalization (p<0.0001). The adjusted effectiveness of complete vaccination was 78% (95% CI: 68-85%) in preventing rotavirus gastroenteritis and 83% (95% CI: 65-93%) in preventing hospitalization for rotavirus gastroenteritis. No differences between the two vaccines were detected (p=0.4523). Both vaccines were highly effective in preventing cases and hospital admissions in children due to rotavirus gastroenteritis.
Asunto(s)
Gastroenteritis/prevención & control , Hospitalización/estadística & datos numéricos , Infecciones por Rotavirus/prevención & control , Vacunas contra Rotavirus/administración & dosificación , Vacunas contra Rotavirus/inmunología , Estudios de Casos y Controles , Preescolar , Heces/virología , Femenino , Gastroenteritis/inmunología , Humanos , Lactante , Masculino , Infecciones por Rotavirus/inmunología , EspañaRESUMEN
Objetivo. La histoplasmosis es una infección fúngica causada por el hongo dimórfico Histoplasma capsulatum. En los últimos años, su incidencia en Espa¿na ha aumentado debido, principalmente, a la mayor presencia de población inmigrante procedente de América y al incremento de viajes a dicho continente por turismo o cooperación. Nuestro objetivo ha sido revisar las características clínicas de los casos de histoplasmosis diagnosticados en nuestro centro en los últimos 6 años. Casos clínicos. Se diagnosticaron 4 casos pertenecientes a 4 pacientes de origen sudamericano, 3 de los cuales eran VIH positivos y 1 diagnosticado de dermatomiositis y en tratamiento con fármacos inmunosupresores. El diagnóstico de laboratorio se llevó a cabo mediante estudio anatomopatológico y microbiológico, mediante cultivo y PCR específica directa de la muestra. Discusión. Al tratarse de una infección importada es necesario tener un alto índice de sospecha y realizar una anamnesis detallada, para llegar a su diagnóstico. Es una infección a tener en cuenta en el diagnóstico diferencial del síndrome febril en pacientes inmunodeprimidos, tanto VIH positivos como en tratamiento inmunosupresor, que sean originarios de zonas endémicas o que tengan antecedentes de estancia en ellas(AU)
Objetive. Histoplasmosis is a fungal infection caused by the dimorphic fungi Histoplasma capsulatum. Its incidence in Spain has increased in recent years, mainly due to the increased presence of immigrants from Latin America and increased travel to the continent for tourism and cooperation. Our aim was to review the clinical characteristics of cases of histoplasmosis diagnosed in our hospital during the last six years. Case Reports. We diagnosed 4 cases from 4 patients from South America, 3 ofwhomwere HIV positive and 1 diagnosed with dermatomyositis was treated with immunosuppressive drugs. The laboratory diagnosis was carried out by histological and microbiological study, by culture and specific PCR directly on the sample. Discussion. As it is an imported infection there needs to be a high level of suspicion and a detailed history taken to get a diagnosis. This infection requires a differential diagnosis between febrile syndrome in immunosuppressed patients, both HIV positive and immunosuppressive therapy, which originate from endemic areas, or who have a history of staying in them(AU)
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Histoplasmosis/diagnóstico , Histoplasmosis/terapia , Terapia de Inmunosupresión/instrumentación , Terapia de Inmunosupresión/métodos , Histoplasma/aislamiento & purificación , Histoplasma/patogenicidad , Radiografía Torácica , Histoplasmosis/microbiología , Histoplasmosis/fisiopatología , Terapia de Inmunosupresión/tendencias , Terapia de Inmunosupresión , Anamnesis/métodosRESUMEN
OBJECTIVE: Histoplasmosis is a fungal infection caused by the dimorphic fungi Histoplasma capsulatum. Its incidence in Spain has increased in recent years, mainly due to the increased presence of immigrants from Latin America and increased travel to the continent for tourism and cooperation. Our aim was to review the clinical characteristics of cases of histoplasmosis diagnosed in our hospital during the last six years. CASE REPORTS: We diagnosed 4 cases from 4 patients from South America, 3 of whom were HIV positive and 1 diagnosed with dermatomyositis was treated with immunosuppressive drugs. The laboratory diagnosis was carried out by histological and microbiological study, by culture and specific PCR directly on the sample. DISCUSSION: As it is an imported infection there needs to be a high level of suspicion and a detailed history taken to get a diagnosis. This infection requires a differential diagnosis between febrile syndrome in immunosuppressed patients, both HIV positive and immunosuppressive therapy, which originate from endemic areas, or who have a history of staying in them.
Asunto(s)
Histoplasmosis/diagnóstico , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , América del Sur/etnología , EspañaRESUMEN
We present a case of mixed infection by two filariae (Loa loa and Mansonella perstans). It seems that the infection was suspected due to a pronounced eosinophilia in a routine analysis. Sheathed and unsheathed microfilariae were observed in the spread of peripheral blood, which enabled a diagnosis to be established of mixed infection by filariae. The definitive diagnosis of the species was carried out at the National Centre of Microbiolgy of Majadahonda. A treatment was initiated with dietilcarbamazina and mebendazole which resulted in the patient's being cured and in the elimination of the microfilariae in the patient's blood. Filariasis is still endemic in many countries. Due to the increase of travellers to such zones and the migratory movements from such areas it is not unusual for us to come across such a diagnosis. The implantation of massive treatments against filariae in endemic zones by the World Health Organisation is reducing their transmission and is managing to eliminate the disease in some areas.
Asunto(s)
Loiasis/complicaciones , Anciano , Infecciones por Dipetalonema/complicaciones , Femenino , Guinea , Humanos , MansonellaRESUMEN
IntroducciónSe estudiaron los genotipos circulantes de Chlamydia trachomatis que causan infección en nuestra área geográfica con el fin de detectar posibles peculiaridades epidemiológicas.MétodosSe genotiparon 177 cepas obtenidas entre 2006 y 2008 empleando una reacción en cadena de la polimerasa con cebadores del gen ompA y posterior secuenciación.ResultadosLos genotipos más frecuentes fueron el E (45,3%), el D (15,3%), el G (10,2%) y el F (9,6%). Otros genotipos encontrados fueron B, H, I, J, K y LGV II.ConclusiónLa técnica empleada tuvo una alta rentabilidad (89%) (AU)
IntroductionCirculating Chlamydia trachomatis genotypes that cause infection in our geographic area were studied with the aim of detecting possible epidemiological peculiarities.MethodsA total of 177 strains obtained between 2006 and 2008 were genotyped using a PCR with primers targeting the ompA gene, and later sequenced.ResultsThe most frequent genotypes were: E (45.3%), D (15.3%), G (10.2%) and F (9.6%). Other genotypes found were: B, H, I, J, K and LGV II.ConclusionThe molecular assay used had a high yield (89%) (AU)
Asunto(s)
Humanos , Masculino , Femenino , Lactante , Preescolar , Niño , Adolescente , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Chlamydia trachomatis/genética , Genotipo , EspañaRESUMEN
INTRODUCTION: Circulating Chlamydia trachomatis genotypes that cause infection in our geographic area were studied with the aim of detecting possible epidemiological peculiarities. METHODS: A total of 177 strains obtained between 2006 and 2008 were genotyped using a PCR with primers targeting the ompA gene, and later sequenced. RESULTS: The most frequent genotypes were: E (45.3%), D (15.3%), G (10.2%) and F (9.6%). Other genotypes found were: B, H, I, J, K and LGV II. CONCLUSION: The molecular assay used had a high yield (89%).
Asunto(s)
Chlamydia trachomatis/clasificación , Chlamydia trachomatis/genética , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Chlamydia trachomatis/aislamiento & purificación , Femenino , Genotipo , Humanos , Lactante , Masculino , Persona de Mediana Edad , España , Adulto JovenRESUMEN
BACKGROUND AND OBJECTIVE: The 7-valent pneumococcal conjugate vaccine (PCV7) has been commercialized in Spain since June 2001. We aim to evaluate the impact of this vaccine in the incidence of invasive pneumococcal disease (IPD) in Navarre. POPULATION AND METHOD: The laboratories of microbiology of Navarre declare all the isolations of Streptococcus pneumoniae in samples of normally sterile corporal fluids. We analyzed the incidence of IPD in children younger than 5 years between weeks 41 of 2000 and 40 of 2005. RESULTS: The doses of PCV7 sold up to 2005 would provide a cover of 27% in children younger than 5 years, having assumed 4 dose schedules. In the 5 seasons, 103 cases of IPD were diagnosed. From the 2 first seasons (2000-2002) to the last one (2004-2005) a reduction of 69% in the incidence rate of IPD caused by vaccine serotypes was observed (from 33 to 10 cases by 100,000 children under 5 years; p = 0.003). Between those same periods the incidence of IPD caused by non-vaccine serotypes increased a 36% (from 42 to 57 by 100,000; p = 0.405). The global incidence of IPD diminished a 12% (from 77 to 67 by 100,000; p = 0.689). The percentage of cases that had received PCV7 increased until 45% in season 2004-2005 (p < 0.001). The meningitis and bacteraemic pneumonias supposed 42% of the IPD, without significant changes during the period (p = 0.442). CONCLUSIONS: Since the PCV7 was marketed the pattern of serotypes has changed, but the expected reduction in the total IPD incidence has not been achieved.
Asunto(s)
Vacunas Meningococicas , Infecciones Neumocócicas/prevención & control , Vacunas Neumococicas , Preescolar , Vacuna Neumocócica Conjugada Heptavalente , Humanos , Incidencia , Lactante , Infecciones Neumocócicas/epidemiología , España/epidemiologíaRESUMEN
Fundamento y objetivo: Desde junio de 2001 se comercializa en España la vacuna neumocócica conjugada heptavalente (VNC7v). Nuestro objetivo ha sido evaluar su impacto en la incidencia de enfermedad neumocócica invasiva (ENI) en Navarra. Población y método: Los laboratorios de microbiología de Navarra declaran todos los aislamientos de neumococo en muestras de fluidos corporales normalmente estériles. Analizamos la incidencia de ENI en niños menores de 5 años entre las semanas 41 de 2000 y 40 de 2005. Resultados: Las dosis de VNC7v vendidas hasta 2005 permitirían alcanzar una cobertura del 27% en menores de 5 años, suponiendo 4 dosis por niño. Entre las 5 temporadas se diagnosticaron 103 casos de ENI. Comparando la incidencia de ENI en las 2 primeras temporadas (2000-2002) con la última (2004-2005), se observa un descenso del 69% en la tasa por serotipos vacunales (de 33 a 10 casos por 100.000 menores de 5 años; p = 0,003). Entre esos mismos períodos, la incidencia de ENI por serotipos no vacunales aumentó un 36% (de 42 a 57 por 100.000; p = 0,405). La incidencia global de ENI disminuyó un 12% (de 77 a 67 por 100.000; p = 0,689). El porcentaje de casos que habían recibido VNC7v aumentó hasta el 45% en la temporada 2004-2005 (p < 0,001). Las meningitis y neumonías bacteriémicas supusieron el 42% de las ENI, sin cambios significativos durante el período (p = 0,442). Conclusiones: Tras la comercialización de la VNC7v ha cambiado el patrón de serotipos, pero no se ha conseguido el descenso esperado de la incidencia global de ENI
Background and objective: The 7-valent pneumococcal conjugate vaccine (PCV7) has been commercialized in Spain since June 2001. We aim to evaluate the impact of this vaccine in the incidence of invasive pneumococcal disease (IPD) in Navarre. Population and method: The laboratories of microbiology of Navarre declare all the isolations of Streptococcus pneumoniae in samples of normally sterile corporal fluids. We analyzed the incidence of IPD in children younger than 5 years between weeks 41 of 2000 and 40 of 2005. Results: The doses of PCV7 sold up to 2005 would provide a cover of 27% in children younger than 5 years, having assumed 4 dose schedules. In the 5 seasons, 103 cases of IPD were diagnosed. From the 2 first seasons (2000-2002) to the last one (2004-2005) a reduction of 69% in the incidence rate of IPD caused by vaccine serotypes was observed (from 33 to 10 cases by 100,000 children under 5 years; p = 0.003). Between those same periods the incidence of IPD caused by non-vaccine serotypes increased a 36% (from 42 to 57 by 100,000; p = 0.405). The global incidence of IPD diminished a 12% (from 77 to 67 by 100,000; p = 0.689). The percentage of cases that had received PCV7 increased until 45% in season 2004-2005 (p < 0.001). The meningitis and bacteraemic pneumonias supposed 42% of the IPD, without significant changes during the period (p = 0.442). Conclusions: Since the PCV7 was marketed the pattern of serotypes has changed, but the expected reduction in the total IPD incidence has not been achieved
Asunto(s)
Masculino , Femenino , Lactante , Preescolar , Humanos , Infecciones Neumocócicas/epidemiología , Meningitis Neumocócica/epidemiología , Vacunas Neumococicas/farmacocinética , Streptococcus pneumoniae/patogenicidad , Monitoreo Epidemiológico , Control de Enfermedades Transmisibles/tendenciasRESUMEN
Fundamento y objetivo: La hipertrofia ventricular izquierda (HVI) es la enfermedad cardíaca más frecuente en hipertensos. El objetivo es conocer la prevalencia de HVI en población hipertensa de larga evolución tratada en el ámbito de atención primaria (AP), así como su perfil epidemiológico. Pacientes y método: Estudio descriptivo, transversal y multicéntrico, de 915 hipertensos que acudieron consecutivamente a consultas de AP y llevaban más de 5 años en tratamiento farmacológico. Se midió la presión arterial y se realizó anamnesis y registro de datos electrocardiográficos y bioquímicos. Se evaluó la HVI según criterios de Cornell y/o Sokolow-Lyon. Resultados: La población estudiada (el 63% mujeres) tiene una media de edad de 68,7 años; el 31,6% son diabéticos y el 37,5% tiene la presión arterial controlada. El 30,5% presenta criterios electrocardiográficos de HVI, con mayor prevalencia en mujeres; asimismo, las mujeres con HVI tienen una edad más avanzada. El 30% tiene antecedentes de enfermedad cardiovascular y la prevalencia de insuficiencia cardíaca es mayor en pacientes con HVI. El 54% está en politerapia antihipertensiva y no hay diferencias significativas en el tratamiento de los pacientes con y sin HVI. El 77% de los pacientes con HVI cumplen únicamente el criterio de Cornell; el 12%, sólo el de Sokolow-Lyon y el 11%, ambos criterios. Los pacientes que sólo tienen positividad para el criterio de Cornell se caracterizan por predominio del sexo femenino y mayor prevalencia de obesidad. Conclusiones: La prevalencia de HVI, valorada mediante criterios electrocardiográficos, es elevada en hipertensos de larga evolución, especialmente en mujeres. Es preciso insistir en la realización periódica de electrocardiogramas en hipertensos e incrementar el esfuerzo terapéutico
Background and objective: Left ventricular hypertrophy (LVH) is the most frequent manifestation of cardiac damage in hypertension. The objective of this study was to evaluate the prevalence of LVH in hypertensive patients of long evolution at Primary Care (PC) and to describe their epidemiological profile. Patients and method: 915 hypertensive patients treated for more than 5 years with antihypertensive drugs, who were atended in a consecutive way by de PC physicians, were evaluated in a multicentral and descriptive study. Clinical evaluation data together with electrocardiographic (EKG) and laboratory results were recorded. LVH was assessed by the Cornell and/or Sokolow-Lyon criteria. Results: Study population was characterized by a mean age of 68.7 years, 63% women, 31.6% diabetics, and 37.5% presented controlled blood pressure levels. 30.5% of them presented LVH criteria on EKG, being more prevalent among women, and on the other hand, women with LVH were of a greater age. 30% of patients presented history of cardiovascular disease and heart failure was more frequent among those with LVH. 54% were polymedicated with blood pressure lowering drugs, however there were no differences between groups of patients with and without LVH regarding their treatment. The Cornell criterion and the Sokolow-Lyon criterion alone were presented in a 77% and 12% of patients, respectively, and 11% of them were positive for both criteria. Patients with positivity for only the Cornell criterion were characterized by a greater prevalence of women and obesity. Conclusions: The prevalence of LVH assessed by EKG criteria is high among hypertensive population of long evolution. A greater effort is needed to guarantee a periodic EKG performance in hypertensive patients together with a therapeutic strategy improvement
Asunto(s)
Humanos , Hipertrofia Ventricular Izquierda/epidemiología , Hipertensión/complicaciones , Atención Primaria de Salud/estadística & datos numéricos , Antihipertensivos/uso terapéutico , Factores de Riesgo , Obesidad/complicaciones , Estudios TransversalesRESUMEN
BACKGROUND: The 7-valent pneumococcal conjugate vaccine (PCV7) has shown high efficacy in preventing invasive pneumococcal disease (IPD) caused by vaccine serotypes. We aimed to assess the overall effectiveness of PCV7 against IPD in Navarra, Spain. METHODS: All children aged <5 years who were diagnosed with IPD during the period 2001-2005 (n=85) and 5 control subjects per case patient (n=425), individually matched by birth date and birth hospital, were analyzed. Vaccination records were obtained from the regional immunization registry. Conditional logistic regression was used to estimate odds ratios. RESULTS: Eighteen case patients (21%) and 114 control subjects (27%) had received >or=1 dose of PCV7. PCV7 serotypes were responsible for 34 (51%) of the cases in unvaccinated children. The overall effectiveness for case prevention was 31% (odds ratio, 0.69; 95% confidence interval, 0.37-1.27). In a separate analysis, vaccination with PCV7 was 88% effective in preventing IPD due to vaccine serotypes (odds ratio, 0.12; 95% confidence interval, 0.02-0.91) and was associated with a higher risk of IPD due to nonvaccine serogroups (odds ratio, 6.16; 95% confidence interval, 1.63-23.3). CONCLUSIONS: These data reveal a higher risk of IPD caused by non-PCV7 serogroups among vaccinated children. Consequently, the overall effectiveness of PCV7 for IPD prevention may be greatly reduced.